Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence
Woelsung Yi, … , Derek B. Sant’Angelo, Lisa K. Denzin
Woelsung Yi, … , Derek B. Sant’Angelo, Lisa K. Denzin
Published March 1, 2010
Citation Information: J Clin Invest. 2010;120(4):1324-1336. https://doi.org/10.1172/JCI40220.
View: Text | PDF
Research Article Immunology

Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence

  • Text
  • PDF
Abstract

Peptide loading of MHC class II (MHCII) molecules is directly catalyzed by the MHCII-like molecule HLA-DM (DM). Another MHCII-like molecule, HLA-DO (DO), associates with DM, thereby modulating DM function. The biological role of DO-mediated regulation of DM activity in vivo remains unknown; however, it has been postulated that DO expression dampens presentation of self antigens, thereby preventing inappropriate T cell activation that ultimately leads to autoimmunity. To test the idea that DO modulation of the MHCII self-peptide repertoire mediates self tolerance, we generated NOD mice that constitutively overexpressed DO in DCs (referred to herein as NOD.DO mice). NOD mice are a mouse model for type 1 diabetes, an autoimmune disease mediated by the destruction of insulin-secreting pancreatic β cells. Our studies showed that diabetes development was completely blocked in NOD.DO mice. Similar to NOD mice, NOD.DO animals selected a diabetogenic T cell repertoire, and the numbers and function of Tregs were normal. Indeed, immune system function in NOD.DO mice was equivalent to that in NOD mice. NOD.DO DCs, however, presented an altered MHCII-bound self-peptide repertoire, thereby preventing the activation of diabetogenic T cells and subsequent diabetes development. These studies show that DO expression can shape the overall MHCII self-peptide repertoire to promote T cell tolerance.

Authors

Woelsung Yi, Nilufer P. Seth, Tom Martillotti, Kai W. Wucherpfennig, Derek B. Sant’Angelo, Lisa K. Denzin

×

Figure 7

NOD.DO DCs display an altered MHCII peptide repertoire.

Options: View larger image (or click on image) Download as PowerPoint
NOD.DO DCs display an altered MHCII peptide repertoire.
(A) Splenocytes ...
(A) Splenocytes from NOD and NOD.DO mice were stained with a mAb specific for CD11c and the anti-MHCII mAbs 10-2.16, OX-6, and AMS-32.1. Top panel shows surface I-Ag7 levels for NOD and NOD.DO mice, and bottom panel shows surface and intracellular (total) I-Ag7 levels obtained by permeabilizing cells after surface staining and restaining. (B) Quantification of 10-2.16, OX-6, and AMS-32.1 DC levels (MFI) obtained for multiple animals (n = 6 of each). Data represent mean ± SEM. The numbers in the NOD.DO bar graphs represent the average MFI of NOD.DO DC I-Ag7 levels relative to that obtained for NOD. Data are representative of 4 (10-2.16), 2 (AMS-32.1), and more than 20 (OX-6) similar experiments. (C) Splenocytes from NOD and NOD.DO mice were stained with anti-CD19 and anti-MHCII mAbs 10-2.16, OX-6, and AMS-32.1, made permeable and stained with a mAb specific for DO. Histograms show I-Ag7 levels in CD19+ B cells from NOD mice and DO+ and DO– CD19+ B cells from NOD.DO mice (determined by gating on B cells staining positive or negative for DO). (D) Quantification of 10-2.16, OX-6, and AMS-32.1 surface B cell levels (MFI) obtained for multiple animals (n = 4 of each). Data represent mean ± SEM. Data are representative of 2 similar experiments. (E) DO expression levels (MFI) in DO+ B cells and DCs from NOD.DO mice. Each symbol represents an individual mouse (n = 5), and horizontal bars represent the means. Data are representative of 3 similar experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts